Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Vanda Vaults From Dog House to Drug Approval
- If there was one biotech on every banker's list of cash shells, one dog that could make bankruptcy look like a good option, one name synonymous with snickers and snide comments, it was Vanda Pharmaceuticals. Which makes the FDA's approval of Vanda's schizophrenia drug Fanapt iloperidone surprising, to say the least. ...
- Blog posts 2009-05-08
Additional Resources
- Vanda reaps $200M upfront in Novartis drug pact
- Shares of Vanda Pharmaceuticals swiftly shot up this morning after the developer announced a new licensing deal with Novartis that will be worth up to $265 million--with a whopping $200 million of that coming in an upfront payment. Novartis is paying for the exclusive rights to market Vanda's...
- News items 2009-10-13
- Vanda Pharmaceuticals: Heavily Undervalued
- Vanda Pharmaceuticals VNDA is making a stunning come back this year as FDA finally approved its schizophrenia drug Fanapt. But the story is far from over, and there is every reason to believe VNDA is still heavily undervalued and has huge upside potential. This is a potential giant market for...
- External links 2009-07-08
- Vanda/Novartis: ... And the Circle of Life is Complete
- The surprise approval of iloperidone Fanapt earned back in May by Vanda Pharmaceuticals had a lot of people (OK maybe just us?) scratching their heads to come up with comparable instances of molecules that were dumped by pharma and eventually made it to market. Like our lion king friends here,...
- News items 2009-10-13
- Vanda Pharma Surges on FDA Approval
- ValueHuntr submits: Shares of Vanda Pharmaceuticals Inc. VNDA skyrocketed today after the company said the FDA approved its schizophrenia drug Fanapt. Vanda plans to begin shipping the drug to pharmacies later this year. The news sent Vanda shares surging nearly tenfold to $10.00 from $1.08. We purchased the stock at...
- External links 2009-05-07
- Vanda Pharmaceuticals Comes Back from the Dead
- Derek Lowe submits: I wrote last summer about Vanda Pharmaceuticals VNDA and their difficulty getting a new antipsychotic Fanapt iloperidone through the FDA. At the time, they'd received one of those wonderful requests for more information from the agency, of the kind that spread cheer whenever they appear. I...
- External links 2009-07-01
- Misys signs partnership agreement with Vanda Group to promote Trade Innovation in China.
- M2 PRESSWIRE-24 February 2004-Misys: Misys signs partnership agreement with Vanda Group to promote Trade Innovation in ChinaC1994-2004 M2 COMMUNICATIONS LTD RDATE:02242004 London - Misys Wholesale Banking Systems today announced the signing of a partnership agreement with Vanda Systems & Communications...
- Research articles 2004-02-24
- Vanda Pharmaceuticals Inc. premieres new stock on Wall Street
- It's probably not the debut Vanda Pharmaceuticals Inc. executives had dreamed of - but it's a start.The Rockville biotechnology company marked its first day as a publicly traded company by dropping 32 cents, or 3.2 percent, to close at $9.68 on the Nasdaq.The initial public offering opened at $10 per...
- Research articles 2006-04-13
- Rockville-based Vanda gets FDA nod
- Vanda Pharmaceuticals Inc., of Rockville, which develops drugs to treat disorders of the central nervous system, said the Food and Drug Administration has officially accepted its New Drug Application for iloperidone for the treatment of schizophrenia. Acceptance of the NDA confirms that the application is sufficiently complete for FDA review....
- Research articles 2007-11-28
- Vanda Pharmaceuticals Inc. of Rockville seeks FDA nod
- Vanda Pharmaceuticals Inc. of Rockville has submitted to the Food and Drug Administration the company's first new drug application, requesting approval to commercialize iloperidone, its atypical antipsychotic treatment for schizophrenia. According to Vanda, iloperidone does not produce some of the serious side effects -- including weight gain and irregular muscle...
- Research articles 2007-09-28
- Vanda seeks FDA nod
- Vanda Pharmaceuticals Inc. of Rockville has submitted to the Food and Drug Administration the company's first new drug application, requesting approval to commercialize iloperidone, its atypical antipsychotic treatment for schizophrenia. According to Vanda, iloperidone does not produce some of the serious side effects -- including weight gain and irregular muscle...
- Research articles 2007-09-28
- Vanda Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Corey Davis from Natexis. Please proceed. Corey Davis – Natexis Thanks very much. I guess in the meaning that you have when you have it with the FDA, what’s ambiguous about the letter that could...
- Earnings calls 2008-09-02
- Vanda Selects Descartes To Provide Internet Logistics Solutions To Asian Marketplace
- Business Wire WATERLOO, Ontario--BUSINESS WIRE--June 28, 2000 Greater China's Largest Systems Integrator To Build DigiLogistics.com Portal With Descartes Technology; Also Forms Alliance To Market and Implement Descartes Solutions In Asia The Descartes Systems Group Inc. (NASDAQ:DSGX)(TSE:DSG.), a leading provider of global Internet logistics solutions, announced...
- Research articles 2000-06-28
- Rockville-based Vanda Pharmaceuticals Inc. cuts loss
- Vanda Pharmaceuticals Inc., of Rockville, which develops drugs to treat disorders of the central nervous system, reported a first- quarter net loss of $15.4 million, or 61 cents per diluted share, on revenue of $16.8 million, versus a net loss of $18.1 million, or $385.61 per diluted share, on revenue...
- Research articles 2007-05-02
- Rockville-based Vanda Pharmaceuticals Inc.'s loss widens
- Vanda Pharmaceuticals Inc., of Rockville, which develops drugs to treat disorders of the central nervous system, said its third- quarter loss widened on higher costs associated with the company's developing schizophrenia drug iloperidone. Losses after paying preferred dividends totaled $21.9 million, or 82 cents per share, compared with a loss...
- Research articles 2007-11-09
- Vanda Pharmaceuticals Inc. shares rise 85 percent to a record high
- Vanda Pharmaceuticals Inc. of Rockville reported positive news yesterday from late-stage trials for its schizophrenia treatment candidate yesterday, sending its share price soaring.
- Research articles 2006-12-08
- Rockville-based Vanda Pharmaceuticals Inc. plans second offering to
- Less than a year after its $53.3 million initial public offering, Rockville-based Vanda Pharmaceuticals Inc. is planning a second stock offering to raise an estimated $92.5 million.
- Research articles 2007-01-10
- Schaeffer's Daily Market Blog Features: Joseph A. Bank Clothiers, Brocade Communications, Vanda, Perry Ellis International, and Parlux Fragrances
- CINCINNATI -- Among the stocks featured in the December 7 edition of Schaeffer's Market Blog are Joseph A. Bank Clothiers (NASDAQ:JOSB), Brocade Communications (NASDAQ:BRCD), Vanda (NASDAQ:VNDA), Perry Ellis International (NASDAQ:PERY), and Parlux Fragrances (NASDAQ:PARL). Schaeffer's Market Blog is just one of the many free market commentaries written every day at...
- Research articles 2006-12-07
- New Analyst Reports for ALBERTA OILSANDS INC, RUBICON MINERALS CORPORATION, ZOLTEK COMPANIES INC, and VANDA PHARMACEUTICALS INC
- MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for ALBERTA...
- Research articles 2008-05-05
- Tang Capital Partners' Proxy Statement for Vanda Pharmaceuticals Calls for Liquidation
- Greenbackd submits: Tang Capital Partners has filed a preliminary proxy statement for the Vanda Pharmaceuticals (Nasdaq: VNDA) 2009 Annual Meeting of Stockholders urging stockholders to support Tang Capital Partners’ slate of two director nominees, Kevin C. Tang and Andrew D. Levin, M.D., Ph.D. We’ve been following VNDA...
- External links 2009-04-09
- << Previous
- page 1 of 1
- Next >>
